Meningococcemia secondary prevention: Difference between revisions

	Meningococcemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Meningococcemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Treatment
Medical Therapy
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Meningococcemia secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Meningococcemia secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Meningococcemia secondary prevention
CDC on Meningococcemia secondary prevention
Meningococcemia secondary prevention in the news
Blogs on Meningococcemia secondary prevention
Directions to Hospitals Treating Meningococcemia
Risk calculators and risk factors for Meningococcemia secondary prevention

Latest revision as of 18:03, 18 September 2017

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

@@ Line 1: / Line 1: @@
 __NOTOC__
+Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
 {{Meningococcemia}}
-{{CMG}}
-==Secondary Prevention==
-The most important form of prevention is a vaccine against ''[[Neisseria meningitidis]]''.  Different countries have different strains of the bacteria and therefore use different vaccines.  Five serogroups, A, B, C, Y and W135 are responsible for virtually all cases of the disease in humans. Vaccines are currently available against four of the five strains, and a vaccine against the B strain is in development. Menactra and Menomune are two commonly used vaccines. Unfortunately, there is currently no evidence that any of the current vaccines offer significant protection beyond three years.
-Additionally, basic [[hygiene]] measures, such as hand washing and not sharing drinking cups, can reduce the incidence of infection by limiting exposure.
-When a case is confirmed, all close contacts with the infected person can be offered [[antibiotics]] to reduce the likelihood of the infection spreading to other people.
 ==References==
 {{Reflist|2}}
-[[Category:Needs overview]]
+[[Category:Needs content]]
 [[Category:Dermatology]]
 [[Category:Emergency medicine]]
 [[Category:Hematology]]
-[[Category:Infectious disease]]
 [[Category:Neurology]]
 [[Category:Pediatrics]]